# FVC, FEV<sub>1</sub> and FEV<sub>1/</sub> FVC % in Rheumatoid Arthritic Female and their Relationships with Duration of the Disease

FarzanaYesmin<sup>1</sup>,Shelina Begum<sup>2</sup>, Sultana Ferdousi<sup>3</sup>

### Abstract

Background: Rheumatoid Arthritis (RA) is the most common inflammatory disorder mediated through the immune system, affecting joints and various organs including lungs. Pulmonary dysfunction in RA patients has been reported. Objective: To observe FVC, FEV1 and FEV1/FVC % in female patients of RA and their relationships with duration of the disease. Methods: This cross-sectional study was carried out in the Department of Physiology, BSMMU, Dhaka, from January to December 2009 on 90 RA female patients of 30-50 years age (Group B). For comparison, 30 age and BMI matched apparently healthy subjects (Group A) were also studied. According to the duration of disease, RA patients were subdivided into  $B_1$  (newly diagnosed),  $B_2$  (3-5 years) and  $B_3$  (6-10 years). They were selected from the Out Patient Department of Physical Medicine of Bangabandhu Sheikh Mujib Medical University, Dhaka. FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC% of all the subjects were measured by a digital MicroDL spirometer. Results were expressed as percent of predicted value. For statistical analysis One-Way ANOVA, Unpaired Student's 't' test and Pearson's correlation coefficient test were performed, as required. **Results:** The mean percentage of predicted values of these lung function parameters in the healthy female subjects and newly diagnosed  $(B_1)$  RA patients were within normal ranges. The mean percentage of predicted values of all the spirometric variables were significantly lower in the patients in  $B_2$ compared to those in B<sub>2</sub> (FVC p<0.01, FEV<sub>1</sub> p<0.01), B<sub>1</sub> (FVC p<0.05, FEV<sub>1</sub> p<0.05, FEV<sub>1</sub>/FVC% p< 0.001) and A (FVC p<0.01, FEV1 p<0.001, FEV1/FVC% p<0.001), except FEV1/FVC% in B3 vs B2 which was lower but nonsignificant. Again these same parameters were significantly lower in  $B_2$  in comparison to B<sub>1</sub> (FVC p<0.001, FEV<sub>1</sub> p<0.001, FEV<sub>1</sub>/FVC% p<0.001) and A (FVC p<0.001, FEV<sub>1</sub> p<0.05, FEV<sub>1</sub>/ FVC% p<0.001). In addition all the ventilatory variables had significant (p<0.001) negative correlation with durations of disease except FVC in  $B_1$ , which was significant at p<0.01 level. **Conclusion:** This study reveals that pulmonary functions may be lower in patients of RA and the lung function is inversely related to the duration of disease.

Key Words: FVC; FEV<sub>1</sub>, Rheumatoid Arthritis

J Bangladesh Soc Physiol. 2010 June; 5(1): 8-13 For author affiliations, see end of text. http://www.banglajol.info/index.php/JBSP

### Introduction

heumatoid Arthritis (RA) is the most common inflammatory disorder mediated through the immune system. Typical clinical features of RA include symmetrical, deforming small and large joint polyarthritis, associated with systemic disorder and extra-articular features <sup>1</sup>. Women are 2 to 3 times more affected than men. Onset may be at any age, most frequently occur between 35 to 50 year<sup>2</sup>.

The etiology of Rheumatoid Arthritis is still unknown, but there is evidence for genetic predisposition to the disease<sup>3</sup>. A good number

J Bangladesh Soc Physiol. 2010 June; 5(1): 8-13

FVC, FEV1 and FEV1/ FVC % in Rheumatoid Arthritics

of investigators reported association of abnormal pulmonary function tests in RA patients <sup>4-8</sup>.

Pulmonary involvement contributes significantly to the morbidity and mortality in patients with Rheumatoid Arthritis and is the second most common cause of death <sup>6</sup>. It has been observed that Rheumatoid Factor (RF) value was significantly higher in the presence of lung involvement in RA patients <sup>9</sup>.

Researchers agreed that immune mediated processes in Rheumatoid Arthritis are vital to the inflammatory processes in the lung. Immune complex deposits in the lung interstitium and alveolar walls leads to alveolar macrophage activation <sup>9</sup>. Inflammatory processes on air sacs or alveoli and their supporting structures make them fibrosed resulting in impaired lung function<sup>10, 11</sup>.

Some investigators claimed chronic airway disease was the predominant one <sup>12</sup> but small airway involvement may appear as the commonest form of pulmonary involvement of rheumatoid lung disease though Interstitial Lung Disease (ILD) is the most common form of pulmonary abnormality <sup>9</sup>. Rheumatoid pulmonary disorders may range from pleurisy, pulmonary nodules and interstitial pulmonary fibrosis to airway disease <sup>5</sup>.

Some researchers reported that lung functions tests were correlated with duration of disease <sup>13,14</sup>. Large numbers of subjects in Bangladesh are affected by Rheumatoid Arthritis. Usually the patients are treated by the physician with an aim to relieve the symptoms, ignoring the prevention of complications. Therefore, pulmonary involvements in RA may remain undiagnosed which can be easily diagnosed by simple pulmonary functions tests. Therefore, pulmonary functions tests in these patients are vital for early detection of associated pulmonary involvement in RA patients.

Many researchers have investigated pulmonary functions in this group of patients in other

J Bangladesh Soc Physiol. 2010 June; 5(1): 8-13

countries <sup>6,7,8,15,16</sup>. To the best of our knowledge no such study has been under taken to explore the pulmonary function status in RA patients in Bangladesh. Therefore the present study was conducted to observe some aspects of lung function status in the groups of RA patients and also to evaluate their relationships with duration of this disease.

# Methods

This cross-sectional study was carried out in the Department of Physiology, BSMMU, Dhaka, from January to December 2009 on 90(ninety) female patients of Rheumatoid Arthritis (according to American Rheumatism Association 1987 revised criteria)<sup>17</sup> aged 30-50 yrs (Group B). For comparison 30 age and BMI matched apparently healthy female subjects were also studied (Group A). Based on duration of disease, study group was further divided into Group B<sub>1</sub> (newly diagnosed), Group B<sub>2</sub> (2-5 years) and Group B<sub>3</sub> (6 -10 years). All the patients of study group (Group B) were selected from the Out Patient Department (OPD) of Physical Medicine, BSMMU. Subjects with history of anyform of tobacco, asthma, COPD, pulmonary fibrosis, pneumonia, hypertension (>140/90 mm of Hg), diabetes mellitus (Serum glucose 2hr after breakfast>11mmol/L), any heart disease, chronic renal failure (Serum creatinine>1.5mg/dl), severe anemia (Hb<11mg/dl) were excluded from the study. After selection all the subjects were thoroughly informed about the aim, objectives and benefits of this study to encourage their voluntary participation. informed written consent was taken from each of them. A detail personal, family and medical history were taken and a thorough physical examinations of each subject was done. All the information were recorded in a prefixed questionnaire. Then the subjects were taken to the Respiratory Laboratory for pulmonary function test. The detailed procedure of spirometric examination was explained to the subject and the values of FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/ FVC% were obtained according to the manufacturer's instruction by a Digital Micro DL Spirometer manufactured by Clement Clarke International Ltd .Edinburgh Way ,Harlow,Essex

# Article

CM20 2TT England. Data were analyzed by Oneway ANOVA, Independent sample 't' test and Pearson's Correlation Coefficient test, as applicable.

### Results

The mean  $\pm$  SD age and BMI of all subjects were almost similar and the groups were matched for age and BMI.(Table I).

Groups	n	Age (Year)	BMI (Kg/m <sup>2</sup> )
A	30	38.2±6.02	22.56±1.07
B <sub>1</sub>	30	38.03±5.96	22.79±1.45
B <sub>2</sub>	30	37.7±4.84	22.72±1.45
B <sub>3</sub>	30	40.93±5.21	22.70±1.30

 Table I: Age and BMI in different groups (n=120)

Statistical analysis:

Groups	ps P value		
$\overline{\text{A vs B}_1 \text{ vs B}_2 \text{ vs}}$	B <sub>3</sub> <sup>a</sup> 0.094 <sup>ns</sup>	0.925 <sup>ns</sup>	
A vs $B_1^{b}$	0.827 <sup>ns</sup>	0.193 <sup>ns</sup>	
A vs $B_2^{b}$	0.096 <sup>ns</sup>	0.095 <sup>ns</sup>	
A vs $B_3^{b}$	0.440 <sup>ns</sup>	0.271 ns	
$B_1 vs B_2^{b}$	0.162 <sup>ns</sup>	0.793 <sup>ns</sup>	
$B_2 vs B_3^{b}$	0.284 <sup>ns</sup>	0.547 <sup>ns</sup>	
$B_1 vs B_3 b$	0.613 <sup>ns</sup>	0.763 <sup>ns</sup>	

Data were expressed as mean  $\pm$  SD.

 $\label{eq:a} \begin{array}{ll} a = \mbox{one way ANOVA}, & b = \mbox{independent sample } t \mbox{-test.} \\ \\ BMI = Body \mbox{ Mass Index.} \end{array}$ 

Group A: Apparently healthy subjects (control group)

Group B : Rheumatoid Arthritis (study group)

- B<sub>1</sub>: Newly diagnosed patients.
- B<sub>2</sub>: Patients with 3-5 yrs.
- $B_3$ : Patients with 6-10 yrs.
- ns = non significant (p > 0.05)

n = number of subjects

The mean percentage of predicted values of all these parameters were significantly lower in  $B_2$  and  $B_3$  in comparison to those of group A. Though these values were lower in  $B_1$  compared to A but it was statistically not significant. Again these values were

FVC, FEV1 and FEV1/ FVC % in Rheumatoid Arthritics

significantly lower in  $B_2$  than those of  $B_1$ . In addition these values were also lower in  $B_3$  then those of  $B_2$  but the differences were statistically significant (p<0.05) only for FVC and FEV<sub>1</sub>. (Table II).

Table	e II: Perc	entage of predicted values of FVC,
FEV	1 and FEV	<sub>1</sub> /FVC in different groups (n=120)

Groups n		FVC (% of	$FEV_1$ (% of	FEV <sub>1</sub> /FVC			
		predicted	predicted	(% of predicted			
		value)	value)	value)			
А	30	92.97±11.02	$94.93 \pm 8.12$	$105.07\pm7.26$			
B <sub>1</sub>	30	$90.9 \pm 7.03$	$89.4\pm5.99$	$101.37\pm6.96$			
$B_2$	30	$87.6 \pm 21.87$	73.03 ± 12.79	$88.6 \pm 17.64$			
B <sub>3</sub>	30	63.3±13.97	$57 \pm 14.57$	$83.9\pm20.57$			
Statis	Statistical analysis:						
Groups			P value				
$\overline{\text{A vs B}_1 \text{ vs}}$		0.000***	0.000***	0.000***			
B <sub>2</sub> vs B <sub>3</sub> <sup>a</sup>							
A vs $B_1^{b}$		0.560 ns	0.075 ns	0.846 <sup>ns</sup>			
A vs B <sub>2</sub> <sup>b</sup>		0.000***	0.04*	0.000***			
A vs B <sub>3</sub> <sup>b</sup>		0.009**	0.000***	0.000***			
B <sub>1</sub> vs B <sub>2</sub> <sup>b</sup>		0.000***	0.000***	0.000***			
B <sub>2</sub> vs B <sub>3</sub> <sup>b</sup>		0.024*	0.04*	0.972			
B <sub>1</sub> vs B <sub>3</sub> <sup>b</sup>		0.028*	0.000***	<sup>ns</sup> 0.001***			

Data were expressed as mean  $\pm$  SD.

a = one way ANOVA, b = independent sample t - test. Group A: Apparently healthy subjects (control group)

Group B: Rheumatoid Arthritis (study group)

B<sub>1</sub>: Newly diagnosed patients.

 $B_2$ : Patients with 3-5 yrs.

 $B_3$ : Patients with 6-10 yrs.

\*\*\* = significant (p<0.001)


- \*\* =significant (P<0.01)
- \* = significant (P<0.05) ns = non significant ( p > 0.05)


Correlations of all these study variables with the duration of the disease in RA patients showed FVC (B<sub>1</sub>r=-0.29, B<sub>2</sub>r=-0.78, B<sub>3</sub>r=-0.83), FEV<sub>1</sub> (B<sub>1</sub>r=-0.74, B<sub>2</sub>r=-0.93, B<sub>3</sub>r=-0.99) and FEV<sub>1</sub>/FVC % (B<sub>1</sub>r=-0.93, B<sub>2</sub>r=-0.94, B<sub>3</sub>r=-0.99) significantly (p<0.001) and negatively correlated with the duration of disease in all the study groups (Figure 1,2,3,).

J Bangladesh Soc Physiol. 2010 June; 5(1): 8-13


FVC, FEV1 and FEV1/ FVC % in Rheumatoid Arthritics









**Figure 1:** Correlation of percentage predicted value of FVC with duration of Rheumatoid Arthritis in study groups (n=90)





**Figure 3:** Correlation of percentage predicted value of  $FEV_1/FVC\%$  with duration of Rheumatoid Arthritis in study groups (n=90)

J Bangladesh Soc Physiol. 2010 June; 5(1): 8-13



 $B_1$ : Newly diagnosed RA female patients  $B_2$ : 3-5 years duration RA female patients  $B_3$ : 6-10 years duration RA female patients

**Figure 2 :** Correlation of percentage predicted value of  $FEV_1$  with duration of Rheumatoid Arthritis in study groups (n=90)

## Discussion

The present study was undertaken to observe some aspects of spirometric variables of pulmonary functions in female patients with Rheumatoid Arthritis. In this study, values of FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/ FVC % of healthy subjects were within normal limit and were almost similar to those reported by different investigators of other countries <sup>8,15,18</sup> as well as in our country <sup>19,20</sup>.

In the current study, all the study parameters in patients of RA with different durations were significantly lower than those of healthy subjects but these values are almost similar in newly diagnosed patient and healthy subjects. Several investigators from different countries<sup>6,8,9,21</sup> observed almost similar findings. Again, these parameters were significantly lower in patients with 3-5 years duration compared to that of newly

# Article

FVC, FEV1 and FEV1/ FVC % in Rheumatoid Arthritics

diagnosed and also in 6-10 years duration than those in 3-5 years duration patients. Similar findings were observed by several investigators<sup>17,22</sup>.

Significant negative correlations of FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC% with the duration of disease in all patients of Rheumatoid Arthritis in the present study is similar to those observed by other investigators<sup>14,15</sup>.

Various mechanisms have been proposed for these observed changes in lung function in Rheumatoid Arthritis. Some investigators suggested that the inflammatory process might spread from other organs to the lung interstitial tissue causing lung inflammation and dysfunction<sup>7</sup>. Continuous systemic inflammatory process brings modification of structural and functional features of bronchi and bronchioles<sup>13</sup>. Again mucosal edema secondary to pre-existing airways inflammation may lead to bronchial narrowing and may cause airways obstruction<sup>18</sup>. Immune complex deposits in the alveolar wall of patients may also cause progressive idiopathic interstitial fibrosis<sup>23</sup>.

Decreased percentage of predicted values of FVC,  $FEV_1$ ,  $FEV_1/FVC\%$ , in patients of Rheumatoid Arthritis in comparison to healthy subjects are most likely due to pulmonary fibrosis and bronchial narrowing as a result of chronic inflammation in lung tissue. Again decreased lung compliance in RA patients may be due to costochondral joint disease or respiratory muscle weakness.

Reduced values of all the lung function parameters in the present study are suggestive of the coexistence of obstructive and restrictive features in the RA patients of the present series which is most likely due to the interstitial fibrosis and airway inflammation as a consequence of the chronic inflammatory processes involved in rheumatoid arthritis. Moreover, in this study, the significant negative correlations of the study variables with different duration of Rheumatoid Arthritis and the significant lowering of these parameters in patients with longer duration of RA also revealed the fact that duration of inflammation influences the degree of deterioration lung function.

### Conclusion

This study reveals that pulmonary functions may be lower in patients of Rheumatoid Arthritis and the lung function is inversely related to the duration of disease.

### Acknowledgement

Authors of this study are thankful to the authority of Department of Physical Medicine, BSMMU, for their nice cooperation for sample collection.

### **Authors affiliations**

- \*1. Dr. Farzana Yesmin , Assistant Professor, Department of Physiology, Shahabuddin medical College.Dhaka. Email: ydr.farzana@yahoo.com
- Prof. Shelina Begum, Chairman, Department of Physiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
- Dr. Sultana Ferdousi, Assistant Professor, Department of Physiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Email: sferdousiratna@ gmail.com

\*For correspondence

### References

- Boon NA, Colledge NR, Walker BR, Hunter JAA. Musculoskeletal Disorder. In: Doherty M, Lanyon P, Ralston SH, editors. Davidson 's Principles and Practice of Medicine. Edinburgh: Churchil Livingstone; 2002. p. 1002-1008.
- Altman RD. Rheumatoid Arthritis (RA): Joint Disorders: Merck Mannual books of Patient symptoms. Porter RS,Kaplan JL, Homeier BP (editors). [Internet]. [Update 2008 Feb; cited 2009 Jun 24]. Available from http://www.merckbooks .com/symptoms/index.htm
- Akil M, Amos RS. ABC of Rheumatology: Rheumatoid Arthritis-I: Clinical Features And Diagnosis. BMJ 1995; 310: 587-90.
- Radoux V, Menard HA, Begin R, Decary F, Koopman WJ. Airways Disease In Rheumatoid Arthritis patients. Arthritis Rheum. 1987; 30: 3.

J Bangladesh Soc Physiol. 2010 June; 5(1): 8-13

### FVC, FEV1 and FEV1/ FVC % in Rheumatoid Arthritics

- Kanat F, Levendoglu F, Teke T. Radiological and functional assessment of pulmonary involvement in the rheumatoid athritis patients. Rheumatol Int. 2007; 27; 459-66.
- Avnon LS, Manzur F, bolotin A, Heimer D, Flusser D, Buskila D, Sukenik S, Abushakra M. Pulmonary Function Testing in Patients with Rheumatoid Arthritis. MAJ. 2009; 12.
- Frank ST, Jogn GW, Lional EHM, Ray FFC. pulmonary Disfunction in Rheumatoid Disease. Chest. 1973; 63: 27-35.
- Banks J, Banks C, Cheong B, Umachandran V, smith AP, Jessop JD, Pritchard MH. An Epidemiological and Clinical Investigation of Pulmonary Function and Respiratory Symptoms in Patients with Rheumatoid Arthritis. Q J Med. 1992; 85: 795-806.
- Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005; 25: 429-35.
- Popp W, Rauscher H, Ritschka L, Braun O, Scherak O, Kolarz G, Zwick H. Prediction of interstitial lung involvement in rheumatoid arthritis. The value of clinical data, chest roentgenogram, lung function and serologic parameters. Chest. 1992; 102: 391-94.
- Carol and Eustice R. What Is Rheumatoid Lung Disease ? [Internet]. [Update 2006 Oct 16;cited 2009 May 21]. Available from http:// arthritis.about.com/od/rheumatoidarthritis/a/ arheumatoidlung. htm
- Mori S, Cho I, Koga Y, Sugimoto M. Comparison of Pulmonary Abnormalities on High-Resolution Computed Tomography in Patients with Early versus Longstanding Rheumatoid Arthritis. J Rheumatol. 2008; 35; 1513-21.
- Vergnenegre A, Pugnere N, Antonini MT, Arnaud M, Melloni B, Treves R, Bonnaud F. Airway obstruction and rheumatoid arthritis. Eur Respir J. 1997; 10: 1072-78.
- Al-Assadi T, Al-Shemery A, Salman S. Correlation of Lung Function with Disease Activity in Rheumatoid Arthritis. OMJ. 2009;24:84-8.

- Hassan WU, Keaney NP, Holland CD, Kelly CA. Bronchial reactivity and airflow obstruction in rheumatoid arthritis.Ann Rheum Dis. 1994; 53: 511-14
- 16. Khadadah ME, Jayakrisman B, Al-Gorair S, Almutairi M, Al-Muradni N, Onadeko B, Malaviya AN. Effects of methotrexate on pulmonary function in patients with Rheumatoid arthritis: a prospective study. Rheumatol Int. 2002; 22: 204-7.
- Arnett FC, Edworthy SM, Bloch DA, MCShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
- Sassoon CSH, Samuel WM, Donald PT, Bayder A, Frank P, Quismorio, Edward S M. Small Airways Function In Nonsmokers With Rheumatoid Arthritis. Arthritis Rheum. 1984; 27: 11.
- Ali MO. Study on some spirometric lung functions status in type 2 diabetic male and their relationship with duration of the disease.[M. Phil Thesis] [Dhaka]: Bangabandhu Sheikh Mujib Medical University.2008. 133p.
- Akhter P. Assessment of some aspects of spirometric lung function status in hypothyroid female. [M. Phil thesis] [Dhaka]: Bangabandhu Sheikh Mujib Medical University. 2009. 130p.
- Cortet B, Perez Th, Roux N, Flipo R-M, Duquesnoy B, Delcambre B, Remy-Jardin M. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis. 1997; 56: 596-600.
- 22. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low- dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology. 2002; 41: 262-67.
- 23. SchernthanerG, Scherak O, Kolarz G, Kummer F. Seropositive Rheumatoid Arthritis associated with decreased diffusion capacity of the lung. Ann. Rheum Dis. 1976;35:258.

# Article